Abstract
DG17 is an orally available prodrug of DG35 (a novel HIV protease inhibitor with variable pharmacokinetics). These studies aimed to optimize DG17 pharmacokinetics by gastric acid neutralization and ritonavir pharmacoenhancement. Both studies were conducted using a randomized, cross-over design in which 6 healthy individuals were administered a single dose of 100mg or 200mg DG17, half with the study intervention (sodium bicarbonate solution in the first study, low dose ritonavir in the second). After a one week washout period, each subject was then administered a second dose of DG17, with the study intervention only administered to the other half. Cmax and AUC increases with gastric acid neutralization were greatest in those with the lowest absorption of DG17 alone. All doses were subsequently given with sodium bicarbonate solution in the second study. Low-dose ritonavir co-administration with DG17 increased DG35 Cmax (median 1437 versus 100 ng/ml, p=0.028) and AUC (median 6975 versus 154ng/ml*hr, p=0.028) compared with DG17 without ritonavir. Plasma DG35 exceeded the IC90 for HIV for ≥ 12 hours following a single DG17/ritonavir dose. No significant adverse events occurred. Single dose DG17 is safe and best administered in a manner preventing gastric acid degradation and with low-dose ritonavir.
Keywords: HIV, protease inhibitor, gastric acid neutralization, pharmacoenhancement
Current HIV Research
Title: Phase 1 Single Dose Studies to Optimize the Pharmacokinetics of DG17, a Novel HIV-Protease Inhibitor Pro-Drug, Using Sodium Bicarbonate and Ritonavir
Volume: 6 Issue: 3
Author(s): Catherine L. Cherry, Jennifer F. Hoy, James S. Rowe, Henry Krum, John Mills and Sharon R. Lewin
Affiliation:
Keywords: HIV, protease inhibitor, gastric acid neutralization, pharmacoenhancement
Abstract: DG17 is an orally available prodrug of DG35 (a novel HIV protease inhibitor with variable pharmacokinetics). These studies aimed to optimize DG17 pharmacokinetics by gastric acid neutralization and ritonavir pharmacoenhancement. Both studies were conducted using a randomized, cross-over design in which 6 healthy individuals were administered a single dose of 100mg or 200mg DG17, half with the study intervention (sodium bicarbonate solution in the first study, low dose ritonavir in the second). After a one week washout period, each subject was then administered a second dose of DG17, with the study intervention only administered to the other half. Cmax and AUC increases with gastric acid neutralization were greatest in those with the lowest absorption of DG17 alone. All doses were subsequently given with sodium bicarbonate solution in the second study. Low-dose ritonavir co-administration with DG17 increased DG35 Cmax (median 1437 versus 100 ng/ml, p=0.028) and AUC (median 6975 versus 154ng/ml*hr, p=0.028) compared with DG17 without ritonavir. Plasma DG35 exceeded the IC90 for HIV for ≥ 12 hours following a single DG17/ritonavir dose. No significant adverse events occurred. Single dose DG17 is safe and best administered in a manner preventing gastric acid degradation and with low-dose ritonavir.
Export Options
About this article
Cite this article as:
Cherry L. Catherine, Hoy F. Jennifer, Rowe S. James, Krum Henry, Mills John and Lewin R. Sharon, Phase 1 Single Dose Studies to Optimize the Pharmacokinetics of DG17, a Novel HIV-Protease Inhibitor Pro-Drug, Using Sodium Bicarbonate and Ritonavir, Current HIV Research 2008; 6 (3) . https://dx.doi.org/10.2174/157016208784324967
DOI https://dx.doi.org/10.2174/157016208784324967 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Anti-IgE Therapy with Omalizumab for Severe Asthma: Current Concepts and Potential Developments
Current Drug Targets Intranasal Drug Delivery to the Central Nervous System: Present Status and Future Outlook
Current Pharmaceutical Design Homocysteine in Neurology: From Endothelium to Neurodegeneration
Current Nutrition & Food Science Current Treatment Options for Alzheimer’s Disease and Parkinson’s Disease Dementia
Current Neuropharmacology Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS) Dilemmas in Diagnosis & Treatment
Current Women`s Health Reviews Searching the Staphylococcal Toxic Shock Syndrome Toxin -1 in Septic Children with negative Cultures: A Comparative Study in Tehran, Iran
Infectious Disorders - Drug Targets Phosphodiesterase Type 5 Inhibitors for the Management of Erectile Dysfunction: Preference and Adherence to Treatment
Current Pharmaceutical Design Alzheimer’s Disease and Antioxidant Therapy: How Long How Far?
Current Medicinal Chemistry The Therapeutic Potential of Neural Stem Cells in Traumatic Brain Injuries
Current Signal Transduction Therapy Is Exenatide Improving the Treatment of Type 2 Diabetes? Analysis of the Individual Clinical Trials with Exenatide
Reviews on Recent Clinical Trials A Randomized, Double-Blind, Placebo-Controlled Trial of Two Doses of Ginkgo Biloba Extract in Dementia of the Alzheimers Type
Current Alzheimer Research Non-Pharmacologic Strategies in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Hold Onto Your Hat! - Handling the Roller Coaster Emotions of the College Application Process
Adolescent Psychiatry The Antiprogestogen Mifepristone: A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Biomass-inspired Semiconductor Photocatalysts for Solar Degradation of Organics
Current Organic Chemistry Guide of Hypertensive Crisis Pharmacotherapy
Cardiovascular & Hematological Disorders-Drug Targets Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Methylphenidate on Cognitive Improvement in Patients with Traumatic Brain Injury: A Meta-Analysis
Current Neuropharmacology